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2ABSTRACT
Over the last decade transcriptional dysregulation and altered epigenetic programs have 
emerged as a hallmark in the majority of hematological cancers. Several epigenetic 
regulators are recurrently mutated in many hematological malignancies. In addition, in 
those cases that lack epigenetic mutations, altered function of epigenetic regulators has 
been shown to play a central role in the pathobiology of many hematological neoplasms, 
through mechanisms that are becoming increasingly understood. This, in turn, has led to the 
development of small molecule inhibitors of dysregulated epigenetic pathways as novel 
targeted therapies for hematological malignancies. In this review, we will present the most 
recent advances in our understanding of the role played by dysregulated epigenetic 
programs in the development and maintenance of hematological neoplasms. We will 
describe novel therapeutics targeting altered epigenetic programs and outline their mode of 
action. We will then discuss their use in specific conditions, identify potential limitations and 
putative toxicities while also providing an update on their current clinical development. 
Finally, we will highlight the opportunities presented by epigenetically targeted therapies in 
hematological malignancies and introduce the challenges that need to be tackled by both 
the research and clinical communities to best translate these novel therapies into clinical 
practice and to improve patient outcomes.
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3INTRODUCTION
Normal hematopoiesis is a finely regulated process sustained by a population of 
hematopoietic stem cells (HSC), located within the bone-marrow in adults, that are able to 
both self-renew and perpetually give rise to differentiated cells throughout the lifetime of 
an individual. The regulated balance between self-renewal and differentiation into 
phenotypically distinct mature cells ensures that blood production is maintained during the 
life-span of an individual [1]. Hematological malignancies arise as a result of dysregulation of 
this ordered process and include a wide spectrum of diseases characterized by differences in 
both their clinical behavior and lineage affected. In broad terms, they can be divided in two 
major groups, myeloid and lymphoid disorders. Within each group, several subtypes are 
described which differ in their phenotypic manifestations and clinical behavior. Myeloid 
malignancies comprise chronic conditions such as the myeloproliferative neoplasms (MPN) 
and myelodysplastic syndromes (MDS), characterized respectively by increased proliferation 
of differentiated cells and ineffective hematopoiesis with cytopenias, and acute myeloid 
leukemia (AML), an aggressive and often rapidly fatal disease presenting with both a block 
in differentiation and increased proliferation. Similarly, lymphoid tumors include both the 
very aggressive and poorly differentiated acute lymphoblastic leukemia (ALL) as well as 
tumors of more mature lymphoid cells, including chronic lymphocytic leukemia (CLL), 
malignant lymphomas and multiple myeloma (MM) which normally arise from more mature 
lymphoid cells and that can behave in both an indolent or more aggressive fashion based on 
a variety of factors including their cell of origin, type and number of mutations and 
interaction with their microenvironment [2, 3].
A practical description of epigenetics is that it relates to aspects of chromatin biology that 
control gene expression without altering DNA sequence, including the role of RNA-based 
processes and alterations, including non-coding RNAs, RNA-editing and RNA 
modifications[4]. Chromatin comprises both DNA and a protein scaffold. Its basic structure, 
the nucleosome core complex, consists of 2 copies of each of the 4 histone proteins (H2A, 
H2B, H3 and H4), forming an octamer with DNA wrapped around it. Linker histones such as 
H1 associate with the nucleosome complex and stabilize DNA wrapping around the 
nucleosome, promoting the formation of higher order chromatin structures. These, in turn, 
influence nucleosome spacing on DNA and potentially regulate gene expression although 
many aspects of these interactions and their consequences remain unclear[5, 6]. 
Accessibility of the transcriptional machinery to chromatin and alterations of gene 
expression is determined by many different modifications of the components of the 
nucleosome complex [7]. Posttranslational modifications (PTM) of histone proteins are 
amongst the most common covalent modifications of chromatin and several different types 
have been described including acetylation, methylation, phosphorylation and ubiquitination. 
Moreover, their role in chromatin biology and regulation of gene expression has become 
increasingly understood[8]. PTM can act in different ways to regulate transcription. They 
can modulate non-covalent interactions between DNA and histone proteins, with 
acetylation being a prime example that is thought to increase chromatin accessibility by 
altering the overall histone charge thereby weakening the DNA-histone interaction. 
Moreover, several histone PTM provide direct and indirect binding sites for proteins that 
either recruit additional epigenetic regulators or components of the transcriptional 
machinery or that contain catalytic function to further alter the histone modification state, 
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enzymes (the so-called “epigenetic writers”) and removed by other enzymes, (“epigenetic 
erasers”). The third class of protein, those that specifically bind to the modifications are 
known as epigenetic “readers” [7]. Overall the role of chromatin structure in the modulation 
of gene expression and other DNA-templated processes, such as replication and DNA repair, 
is the result of a finely modulated and dynamic process carried out by different classes of 
protein that generate or erase specific marks, leading to alterations in chromatin 
accessibility and binding by epigenetic readers and other associated proteins [Figure 1]. In 
addition, the methylation status of DNA can also be modified and this dynamic process has 
been shown to regulate gene expression and potentially other DNA-templated processes 
and will be described in more details later [9].
Modulation of transcriptional programs has been shown to play a key role in the regulation 
of hematopoiesis. Evidence that hematopoietic cells fate decisions often occur through 
epigenetic mechanisms has, in turn, resulted in an increased understanding of the function 
of chromatin modifiers in hematopoiesis [10, 11]. It is thus not surprising that dysregulation 
of this process might contribute to the development of hematological malignancies. 
Corroborating this hypothesis, several genome-scale sequencing studies have demonstrated 
that transcriptional regulators and chromatin modifiers are recurrently mutated in 
hematological malignancies, further suggesting that so called “epigenetic” alterations might 
be central to the development of these neoplasms [12-17]. Moreover, epigenetic changes 
are plastic and potentially reversible and theoretically provide a more attractive therapeutic 
target in comparison to the “fixed” nature of genetic alterations. Indeed preclinical and 
clinical evidence is now gathering in several hematological malignancies that targeting these 
epigenetic alterations can reset altered transcriptional programs, resulting in an improved 
therapeutic outcome for patients. The number of epigenetic regulators reported to be 
mutated/dysregulated in hematological malignancies continues to grow [Table 1]. However, 
in this review, we will focus our attention mostly on the role of those chromatin regulators 
whose role in the pathogenesis and as a potential therapeutic targets in hematological 
malignancies is relatively well understood [18-25] and for whom therapeutic inhibitors have 
been developed and are currently being tested in clinical trials.
THE ROLE OF ALTERED DNA METHYLATION IN HEMATOLOGICAL MALIGNANCIES AND 
MUTANT IDH PROTEINS AS NOVEL THERAPEUTIC TARGETS
Regulation and maintenance of DNA methylation plays a pivotal role in embryonic 
development, cellular differentiation and genome stability[26]. It occurs at the Carbon-5 
position in cytosine nucleotides in the context of a 5’-CpG-3’ dinucleotide. This dynamic 
process results from the balance between active methylation and demethylation. The two 
de novo DNA methyltransferases, DNMT3A and 3B, and the maintenance methyltransferase 
DNMT1 are mainly responsible for DNA methylation [9]. Conversely active cytosine 
demethylation is carried out mostly by the TET (ten eleven translocation) family of DNA 
dioxygenases that oxidize cytosine via a number of intermediates (hydroxycytosine hmC, 
formylcytosine fC and carboxyl-cytosine caC) through reactions utilizing oxygen, Fe(II) and 
-ketoglutarate as cofactors. The base excision repair (BER) pathway, through the enzyme 
thymidine DNA glycosylase (TDG) +/- AID-APOBEC finally leads to the conversion of the hmC, 
fC and caC intermediates produced by the TET proteins back to unmethylated cytosine[27, 
28]. Generally, methylated cytosine (5mC), particularly in promoter CpG islands, appears to 
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chromatin, with an increase in 5hmC documented at the transcriptional start sites of 
expressed pluripotent genes in embryonic stem (ES) cells [29]. However the correlation 
between global methylation changes and gene transcription remains generally poor, which 
might reflect a more complex regulation, contributions from other epigenetic factors and 
also the genomic location position of the CpG dinucleotide.  Finally, in a similar fashion to 
histone PTM, 5mC is also bound by specific methylbinding proteins, presumably to translate 
the DNA methylation signal. Similarly, recent evidence suggests that 5hmC and possibly 5fC 
and 5caC may not just be intermediate stages in demethylation but have independent 
functions through the binding of specific reader proteins, although the identity and exact 
consequences of these interactions for DNA-templated processes is not currently 
understood [30]. 
DNMT3A
Alteration in proteins involved in DNA methylation are frequently seen in hematological 
malignancies. Recurrent mutations in DNMT3A are found in around 20% of patients with 
AML [12, 31], as well as T-ALL and malignant lymphomas [32, 33]. These lesions appear early 
in malignant transformation as “pre-leukemic” mutations [34] and have also been reported 
in individuals that lack hematological abnormalities as “clonal hematopoiesis” [35, 36]. The 
mutations are usually hemizygous and are predicted to result in loss of or an alteration of 
the function of the native protein, with the most frequent mutation found in humans 
(R882H) appearing to act as a dominant negative [37, 38]. Murine bone marrow cells 
carrying either deletion of Dnmt3a or specific loss of function mutations display increased 
self-renewal and the respective mouse models develop a pre-leukemic phenotype, although 
not overt leukemia unless they acquire cooperating mutations[39-41]. Dnmt3a mutant cells 
demonstrate a disrupted methylation profile genomewide, including at CpG rich islands in 
key promoters, however these changes correlate poorly with gene expression changes at 
the same loci [39]. Recently, other genomic regions that might play an equally important 
role in the initiation and/or maintenance of the malignant phenotype have been 
demonstrated to be affected by changes in methylation. In particular, the borders of large 
areas of hypomethylation, so called canyons, spanning genes involved in leukemia 
development have been shown to be particularly affected by loss of function in Dnmt3a 
which result in changes in gene expression levels for the same genes [42]. Finally the effects 
of DNMT3A mutations on leukemia development/establishment might involve other DNA-
templated processes, as recently suggested for its effects on DNA damage sensing [41].
TET proteins
TET proteins also are frequently mutated in hematological malignancies. Mutations of TET2 
were first described in MDS and MPN and subsequently shown to be mutated in other 
myeloid malignancies including AML, with a higher frequency of mutations in patients with 
MDS and chronic myelomonocytic leukemia (CMML)[43, 44]. TET2 mutations are also seen 
in lymphomas, particularly of the mature T-cell variety [45] and similarly have been 
described as clonal hematopoietic lesions[35, 36].  Tet2 knock-out mice display increased 
self-renewal in in vitro and in vivo assays, however, they also require cooperating mutations 
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promoters of some genes involved in differentiation, such as Gata2, with corresponding 
silencing of expression [46]. Overall these findings suggest that DNA methylation plays a 
prominent role in leukemia development. DNA methylation also appears to be particularly 
important in determining the development of pre-leukemic states as indirectly confirmed by 
the high frequency of mutations in epigenetic modifiers that regulate DNA methylation 
amongst patients with clonal hematopoiesis [35, 36]. 
IDH mutations
Despite our improved understanding of their role in the pathogenesis of hematological 
malignancies, mutations in DNMT3A and TET proteins cannot, at the moment, be targeted 
therapeutically. However changes in DNA methylation can also indirectly occur as a 
consequence of mutations in the isocitrate dehydrogenases (IDHs) enzymes. IDHs carry out 
the oxidative decarboxylation of isocitrate to α-ketoglutarate. In humans, three different 
isoforms have been described. IDH3 is a NAD+ dependent mitochondrial isoform whose 
main role is in aerobic energy production via the Krebs cycle[47]. IDH1 and IDH2 are very 
similar NADP+ dependent isoforms involved in other metabolic processes, including lipid 
metabolism and glucose sensing (IDH1) and oxidative respiration (IDH2), and are 
cytoplasmic and mitochondrially localized, respectively [48]. Recurrent mutations in the 
genes encoding IDH1 and 2 have been described in 10-20% of mostly cytogenetically normal 
AML and tend to be mutually exclusive [49-51]. They have been described in up to 45% of 
patients with a rare subtype of lymphoma, angioimmunoblastic T-cell lymphoma (AITL)[52, 
53], and to a lesser degree in MPN and MDS patients[54, 55]. They are also common in 
malignant gliomas [56]. The mutations described are gain-of-function and result in 
neomorphic proteins that bind with increased affinity to the normal IDH product α-
ketoglutarate and subsequently lead to its further reduction to the “oncometabolite” 2-
hydroxyglutarate (2-HG) [57]. Subsequent accumulation of 2-HG in leukemic cells interferes 
with a large family of dioxygenase enzymes that require α-ketoglutarate as an enzymatic co-
factor. These include the catalytic DNA dioxygenase (such as TET proteins), the Jumonji-C 
(JmjC) domain-containing family of histone lysine demethylases and the prolyl hydroxylases 
involved in the degradation of hypoxia inducible factor (HIF) proteins [58, 59]. Inhibition of 
these enzymes results in increases in both DNA and histone methylation and provides a 
mechanistic link between mutations in metabolic enzymes and dysregulated transcriptional 
programs in malignant cells [60, 61]. IDH1/2 and TET2 mutations are generally mutually 
exclusive and patients carrying these mutations exhibit similar DNA methylation profiles, 
further demonstrating their functional equivalence [49, 60]. Prognostically, IDH1/2 
mutations have been reported as being associated with contrasting outcomes and it is likely 
that their prognostic significance will depend on specific mutations type and the presence of 
other compound mutations, as well as patient variables such as age and fitness [49, 62-66].  
Mouse and cellular models of IDH1/2 mutations display defective hematopoietic 
differentiation and expansion of stem/progenitor cells [60, 61, 67]. Hematopoietic-specific 
IDH1 mutant (R132H) conditional knock-in mouse models display marked expansion of HSC 
and myeloid progenitors in hematopoietic organs but do not develop frank leukemia, 
suggesting that secondary mutations are needed for AML development[68]. These findings 
would be consistent with the observation that IDH mutations are often encountered early in 
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finding that they and are commonly found in individuals with clonal hematopoiesis [35, 36]. 
Moreover, the DNA methylation signature within the HSC and myeloid progenitors 
compartments of the knock-in mice was strikingly similar to that observed in AML samples 
carrying IDH1/2 mutations [68] further suggesting that aberrant epigenetic and 
transcriptional programmes play a causative role in the establishment of the disease. Similar 
findings were also shown in a retroviral transduction/transplantation mouse model [69]. 
These findings together with the observed occurrence of these mutations in humans 
suggest that IDH mutations are early pre-leukemic mutations that require additional genetic 
or epigenetic factors to lead to AML development. 
Given the novel gain-of-function nature of the IDH mutations, the recent development of 
inhibitors to mutant IDH1/2 proteins represents an exemplar for therapies targeting altered 
transcriptional programs in AML. Several small molecule inhibitors of both IDH1 and IDH2 
have been developed which dramatically reduce levels of 2-HG and lead to differentiation of 
leukemic cell carrying the specific IDH mutations[18, 67, 69-71]. These effects also correlate 
with global changes in DNA methylation/histone modification state, suggesting that the 
phenotypic effects are at least partially secondary to rewiring of transcriptional programs in 
the leukemic cells [72] [Figure 2]. Clinical grade inhibitors of both IDH1 and IDH2 have now 
been developed with AG-221 (Enasidenib), an oral, potent, reversible, and selective inhibitor 
of the mutant IDH2 protein now being the most advanced. AG-221 has been tested in phase 
1/2 clinical trials for patients with AML and AITL/solid tumors carrying IDH2 mutations 
(NCT01915498, NCT02273739) [Table 2]. The trial in AML has recently fully reported.  Doses 
up to 650mg once daily were well tolerated. However a dose of 100mg once daily was 
shown to achieve good steady-state plasma concentration, 2-HG plasma inhibition and 
clinical activity and was further studied. Overall only 5% of patients discontinued drug due 
to toxicity. A specific side effect reported was the IDH-inhibitor associated differentiation 
syndrome that was managed with corticosteroids and drug interruption. In the expansion 
phase, efficacy was evaluated in AML patients. The overall response rate was 40% in 
relapsed/refractory AML patients with 19% complete remissions (and the remainder 6.8% 
complete remission with incomplete hematologic recovery, 6.3% partial remission and 8% 
morphologic leukemia-free state) with a median overall survival of 9.3 months. In addition, 
11% of patients were able to proceed to bone marrow transplant following their response 
to AG-221. Responses appeared secondary to differentiation of leukemic blasts and were 
not associated with a reduction in the burden of IDH2 mutations. Interestingly, reduction in 
2-HG levels were also observed in non-responders, thus suggesting that either additional 
effects contribute to the efficacy of AG-221 or that reduction of 2-HG levels is not sufficient 
by itself to achieve a clinical response. As also demonstrated for other “epigenetic” 
therapies, time to response could take up to several months, thus highlighting the need to 
judge the efficacy of these therapies differently compared to standard chemotherapeutics 
due to their lack of clear and immediate cytotoxic effects[73, 74]. The promising results 
from this study have led to the design of a phase 3 trial incorporating IDH inhibitors in the 
management of AML patients with IDH mutations at disease presentation that is currently 
recruiting (NCT02577406).
THE EMERGING ROLE OF HISTONE METHYLASES AND DEMETHYLASES AS THERAPEUTIC 
TARGETS IN HEMATOLOGICAL MALIGNANCIES
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methyltransferases (KMTs) and protein arginine methyltransferases (PRMTs)[75]. The 
intermediate metabolite, S-adenosyl methionine (SAM) acts as the universal methyl donor 
in these reactions. Moreover the degree of methylation of each amino acid residue can be 
modulated as lysine can be mono-, di- or tri- methylated while arginine can be mono-, 
symmetrically or asymmetrically di-methylated, with some evidence to suggest specific 
functions for these separate modifications. Histone methylation affects transcription and 
other DNA-templated process by altering the ability of reader proteins to bind to the 
methylated residues[76].  
The functional consequences of histone methylation vary depending on the specific residue 
modified and/or the degree of methylation. Whereas some modifications such as H3K4, 
H3K36 and H3K79 are associated with active transcription, others such as H3K9, H3K27 and 
H4K20 are generally associated with transcriptional repression. Moreover, as already 
mentioned, the degree of methylation can also influence functional outcomes, with H3K9 
being a prime example, as monomethylation is associated with active transcription, but 
trimethylation associates with transcriptional repression [77]. Mutations involving histone 
methyltransferases and/or their aberrant activity have been reported in several 
hematological malignancies and have also been shown to change gene expression programs 
that are central to the development and maintenance of the disease phenotype [13-15, 78-
80].  
MLL mutations and DOT1L
The mixed-lineage leukemia (MLL) genes encode for a family of histone methyltransferases. 
MLL2 (KMT2D) is the most common mutated gene in B-cell lymphomas with an incidence of 
up to 90% in Follicular lymphomas (FL) and up to 30% in Diffuse Large B-cell Lymphomas 
(DLBL). MLL2 tend to acquire mostly point mutations, although indels altering the reading 
frame have also been described, and both of these result in loss of protein function[81, 82]. 
Mechanistically they have been shown to impair the enzymatic activity of MLL2 leading to a 
global reduction in H3K4 methylation. Conditional deletion of MLL2 during B-cell 
development leads to an increase in B-cell proliferation and germinal center (GC) B-cells and 
cooperates with known lymphoma oncogenes such as Bcl2 to increase the incidence of GC 
lymphoma in mouse models. These findings confirm the role of MLL2 as a tumor suppressor 
whose loss early in B-cell development facilitates lymhpomagenesis via global epigenetic 
remodeling and transcriptional changes[83]. 
The MLL1 (KMT2A) gene, also referred to as simply MLL, is instead mostly mutated in AML 
either as a result of a partial tandem duplication or as part of a translocation leading to the 
formation of fusion chimeric protein. MLL is required for normal hematopoiesis and 
embryonic development, as constitutive knock-out mice models are embryonically lethal 
with reduced functional HSC [84, 85]. A similar requirement for adult hematopoiesis has 
also been shown in conditional mouse models [86, 87]. MLL is involved in chromosomal 
translocation in the majority of infantile leukemias and up to 10% of adult leukemias, where 
it is promiscuously rearranged with up to 70 different partners [88]. Interestingly all MLL 
chimeras lose their C-terminus which contains its methyltransferase activity[89]. However 
the vast majority of its many translocation partners are members of multi-subunit protein 
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the most frequent MLL fusion partners (AF4, AF9, AF10, ENL, ELL) are part of either the 
super elongation complex (SEC) or disruptor of telomeric silencing 1-like (DOT1L) containing 
complex [90-92].
DOT1L is the only known histone H3 lysine 79 (H3K79) methyltransferase in mammals, 
where it plays an important role in the regulation of cell proliferation, as demonstrated by 
the effects of its genetic silencing on mitotic spindle formation and cell cycle progression 
[93]. Moreover, H3K79 methylation has also been shown to act as a docking site for the DNA 
repair machinery, thus highlighting a potential role for DOT1L and its specific modifications 
in other DNA-templated processes [94]. DOT1L is also known to interact with other proteins 
that might help to explain some of its specific functions. An example of this is its specific 
interaction with the phosphorylated C-terminal domain of actively transcribing RNA 
polymerase II (RNAPII), an interaction that is critical to ensure it targets H3K79 methylation 
to actively transcribed areas of the genome [95]. Whereas DOT1L is essential for embryonic 
erythropoiesis and development, as demonstrated by the fact that germline Dot1l knockout 
mouse are embryonically lethal [96], its role in adult hematopoiesis appears less crucial. A 
conditional knockout model specific for the hematopoietic compartment, using the Vav-Cre 
recombinase, although causing a moderate-to-severe anemia and leukopenia, did not 
completely eradicate multi-lineage hematopoiesis, suggesting that Dot1l might be at least 
partially dispensable for adult hematopoiesis [97]. Conversely, DOT1L has been shown to be 
critical for the transformation of murine BM by MLL-fusions (especially when members of 
the DOT1L complex such as AF9 and ENL are the fusion partner) [98-100]. These data have 
clinical implications, and suggest a therapeutic window between malignant and normal 
hematopoiesis, thus validating DOT1L as a potential therapeutic target in AML.
Mechanistically, preclinical models demonstrate that MLL-driven leukemias are particularly 
sensitive to disruption/inhibition of DOT1L activity and the subsequent effects on 
specific/direct target genes of the MLL-fusion proteins that demonstrate aberrant H3K79 
methylation patterns [97, 101]. Further supporting this model, DOT1L inhibition and loss of 
H3K79 on target genes of MLL-fusion proteins correlated with specific reduction in the 
expression levels of genes critical for the transforming activity of MLL-fusions, including the 
HOXA cluster genes and orphan homeobox gene MEIS1[97, 100]. Some of the specific 
effects of DOT1L inhibitors in MLL-fusion leukemias might also derive from the direct 
interaction of this methyltransferase with several known partners of MLL-fusions [102-104] 
particularly the AF10 protein, which might lead to the aberrant recruitment of DOT1L to 
gene targets of MLL-fusions. Based on the collective evidence of a prominent role of DOT1L 
in leukemogenesis driven by MLL-fusions, several preclinical studies have been reported 
using DOT1L inhibitors. These inhibitors also work through competitive inhibition of SAM, 
the methyl donor required as a substrate for the methyltransferase activity of DOT1L [20, 
21]. DOT1L inhibitors have been shown to specifically reduce H3K79 methylation marks and 
expression of MLL-fusions target genes in leukemic cells [Figure 3]. The effects on chromatin 
structure and transcription correlate with a reduction in the proliferation and viability of 
MLL-rearrenged leukemias both in vitro and in vivo. Moreover, recent evidence suggests 
that DOT1L inhibitors might be efficacious in other subtypes of AML, thus expanding their 
potential role in AML therapy. Preclinical models of AML associated with other 
leukemogenic fusion, such as NUP98-NSD1, or carrying MLL partial tandem duplication have 
been shown to be sensitive to small molecule inhibition with DOT1L inhibitors, suggesting 
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mutations such as IDH1/2, NPM1c and DNMT3A mutations have also shown to be sensitive 
to DOT1L inhibitors [106-108]. While the exact mechanism underlying DOT1L inhibitor 
sensitivity in IDH1/2 mutant AML remains unknown, in NPM1c mutant leukemias DOT1L 
inhibition resulted in downregulation of HOX and MEIS1 whose expression NPM1c 
leukemias are highly dependent on. Similarly DNMT3A mutant leukemias have been shown 
to rely on DOT1L activity to maintain H3K79 methylation marks specifically at the canyons 
that expand following DNMT3A loss of function. Since expanding canyons marked by 
H3K79me2 are enriched for key genes in leukemia development, such as the HOX cluster 
genes, DOT1L inhibition also results in reduced expression of HOX and MEIS genes in 
DNMT3A mutant leukemias and correlates with reduced cell proliferation, viability and 
increased differentiation [106]. It is also noteworthy that DOT1L chemical inhibition appears 
to be better tolerated than its genetic deletion, as only limited toxicity was observed on 
healthy mice. This might be a result of incomplete inhibition, increased sensitivity of 
leukemic cells and/or methyltransferase-independent functions of DOT1L that are not 
targeted by the inhibitors. However, regardless of the exact mechanisms, the promising 
results provide further support to the clinical utility and further development of these 
inhibitors.
EPZ-5676, the most clinically developed DOT1L inhibitor, has now been in phase 1 clinical 
trials (NCT01684150) in patients with advanced hematological malignancies for a few years. 
The adult dose escalation phase is now complete and despite its pharmacokinetic 
limitations, where it has to be delivered as a continuous infusions of up to 28 days, EPZ-5676 
has been well tolerated with some complete responses observed [109]. An adult MLL-fusion 
specific expansion cohort is now enrolling patients. More recently a pediatric phase 1 study 
in relapsed/refractory MLL-fusion leukemias has also produced a preliminary report 
(NCT02141828), that has shown EPZ-5676 to be well tolerated, albeit that no objective 
responses were observed in this difficult group of patients[110] [Table 2]. However further 
clinical investigation alone or in combination with standard or novel therapies has been 
advocated and such studies are currently under design. 
EZH2 and the PRC2 complex
Polycomb repressive complexes (PRC) are critical regulators of tissue homeostasis and cell 
fate decisions. Two different complexes have been described, PRC1 and PRC2, which act in 
concert to establish and maintain transcriptional repression through post-translational 
histone modifications. PRC2 contains three obligate subunits, SUZ12, EED and either 
EZH1/2, the catalytic components of the complex, and act as H3K27 methyltransferases. 
PRC1 then recognizes the H3K27me marks through its CBX subunit and subsequently 
ubiquitylates H2AK119, resulting in the inhibition of transcriptional elongation, chromatin 
compaction and transcriptional silencing[111]. PRC2 has a critical role in normal 
hematopoiesis, as demonstrated by the effects of loss of EED on adult hematopoiesis. 
However not all its components are equally important for normal hematopoiesis as EZH2 
appears to be dispensable, possibly because of a degree of redundancy with EZH1 [112]. 
Interestingly EZH2 is also the PRC2 component most often implicated in the development of 
hematological malignancies. Genome sequencing studies have identified gain-of-function 
somatic mutations of EZH2, mostly occurring at residue Y641, in around 20 to 30% of GC 
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high grade DLBL and 10% of low-grade FL [15]. Models of gain of function EZH2 mutations 
result in increased di- and tri-methylation activity but reduced monomethylation activity, 
related to a defective recognition of unmodified H3K27 in comparison with wild-type (WT) 
EZH2. The residual WT EZH2 activity however appears to be important as also suggested by 
the fact that EZH2 Y641 mutations are hemizygous, with the mutant lymphomas retaining 
one copy of the WT allele[79, 113]. EZH2 is required for GC development and retroviral or 
transgenic overexpression of EZH2 Y641 leads to the development of both GC hyperplasia 
and high grade lymphoma[113-115]. Mechanistically EZH2 Y641 mutations repress 
transcription of genes involved in B-cell exit from the GC and terminal differentiation and 
cell cycle checkpoint genes such as CDKN1a, through an increase of H3K27 trimethylation at 
their promoters[114]. However mutant EZH2 also appears able to disrupt WT EZH2 function 
on genes normally repressed by the PRC2 complex, aberrantly inducing expression of genes 
such as Hoxc4/a9 and Meis1 that might contribute to lymphoma development. These 
effects appear to be secondary to a global redistribution of H3K27me3 away from focal 
peaks near the transcription start site, that causes activation of certain genes and towards 
gene bodies of other genes leading to their transcriptionally repression [113]. In conclusion 
gain-of-function mutations of EZH2 in lymphomas act as a truly neomorphic mutations 
leading to global changes in chromatin structure and subsequent aberrant transcriptional 
reprogramming that facilitates the development of lymphoma.
 
Somewhat counter-intuitively, loss-of-function mutations of EZH2 have also been described 
in some lymphoid malignancies but mostly in myeloid malignancies including MDS and MPN, 
where they are also associated with a poor prognosis [14, 17, 116]. In T-cell ALL, up to 25% 
of cases have been reported to carry loss-of-function mutations in PRC2 members (mostly 
EZH2)[13] and in early T-cell precursor (ETP) ALL, EZH2 loss-of-function mutations are 
present in almost 50% of patients [78]. EZH2 therefore appears to act as a tumor suppressor 
in both these contexts. In ETP-ALL, EZH2 silencing increased expression of genes involved in 
the development of disease, specifically stem-cell-associated transcriptional programs and 
growth/survival signaling genes [117]. In T-ALL, EZH2 deletion appears mainly to potentiate 
the effects of NOTCH1 signaling, a prominent feature of T-ALL. NOTCH1 binding causes 
eviction of EZH2 from its target gene promoters and a reduction of H3K27me3 in the same 
region. Therefore deletion of EZH2 further increased NOTCH1 binding to its target 
promoters and its silencing increased the in vivo tumorigenic potential of human T-ALL in a 
NOTCH1 dependent model. Furthermore EZH2 silencing resulted in decreased apoptosis 
upon treatment with gamma-secretase inhibitors of NOTCH signaling in human T-ALL cell 
lines [13]. 
The pathogenic role of EZH2 loss in myeloid malignancies is highlighted by the observation 
that hematopoietic specific Ezh2-deficient mice develop MDS and MDS/MPN like disease 
[118]. Three recent reports have shown that Ezh2 deletion in a murine MPN model driven 
by the highly recurrent JAK2V617F mutation, induces a more aggressive disease similar to 
myelofibrosis and increases the repopulation capacity of these cells suggesting a tumor 
suppressor role for Ezh2 in this setting. Mechanistically Ezh2 deletion led to reduction of 
H3K27me3 with concomitant increased H3K27 acetylation through ill-defined mechanism at 
promoter regions of several PRC2 target genes, including oncogenes known to play a role in 
the pathogenesis of myelofibrosis such as Hmga2[119-121]. Conversely in the BCR-ABL 
mutated MPN, chronic myeloid leukemia (CML), EZH2 has emerged as a potential 
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therapeutic target, as CML leukemia initiating cells appear to be particularly dependent on 
EZH2 activity. Either genetic deletion or chemical inhibition of EZH2 leads to significant loss 
of leukemia-initiating potential and disease eradication [122, 123]. In AML EZH2 is rarely 
mutated, however its role has been studied using different models with conflicting results. 
Ezh2 deletion in an established MLL-AF9 driven mouse models of AML resulted in a marked 
reduction of leukemia initiating cells and increased differentiation [124, 125] and prevented 
the transformation to AML in a MDS mouse model via compensatory repression of key 
oncogenic genes by the PRC1 complex [126]. While these findings suggest that EZH2 
mutation or deletion might retard AML establishment, a recent report has highlighted that 
reduced expression of EZH2 and H3K27 methylation in several AML models of established 
disease appears to increase resistance of many AML subtypes to standard chemotherapy or 
more targeted tyrosine kinase inhibitor treatment. These effects appear to be partly 
secondary to de-repression of HOX genes following low EZH2 activity [127]. 
Taken together these data suggest that EZH2 can act both as an oncogene and a tumor 
suppressor depending on the type of mutations, hematological malignancy and cooperating 
mutations. Although inhibitors of EZH2 are now entering the clinical arena in several 
hematological malignancies and particularly lymphomas (NCT02082977, NCT01897571, 
NCT02395601) [Table 2], where they have shown favorable safety and tolerability profile 
with some good responses[80, 128], these preclinical data highlight that pharmacological 
inhibition of EZH2 requires to be specifically targeted to certain type of conditions/patients 
and caution should be taken when considering this therapeutic approach.
Histone demethylases and LSD1
Histone methylation was long considered an irreversible process, until the discovery of 
histone demethylases that demonstrated that it was indeed dynamic. Two main classes of 
histone demethylases (KDM) have been described. One class comprises several enzymes 
sharing the so-called Jumonji (JmjC) domain that act as Fe+2 and α-ketoglutarate dependent 
dioxygenases. The second class of enzymes are a flavin adenine dinucleotide (FAD)-
dependent family of amine oxidases[76] The latter class comprises only two members, 
lysine-specific demethylase (LSD) 1 and 2 [129]. The prototype LSD1 acts mostly as a 
demethylases for the H3K4me1/2 and H3K9me1/2 histone marks, although it can also 
demethylate non-histone proteins, including DNMT1 and TP53[130]. Moreover, LSD1 is a 
multifunctional subunit of both repressive and activating histone-modifying complexes and 
can therefore act as both a transcriptional repressor or activator in a context-specific 
manner [131]. LSD1 has been shown to alter the transcriptional programs of different 
neoplasms [132] and appears to play a significant role in hematological malignancies  [19, 
133, 134]. In AML, LSD1 was previously demonstrated to be part of an MLL super-complex 
associated with sites of active transcription even before its function as a demethylase had 
been uncovered [135]. A recent report used combined analysis of gene-expression data 
from 23 murine MLL-rearranged leukemias to demonstrate a significant correlation 
between LSD1 expression levels and clonogenic potential in methylcellulose-based plating 
assays (a surrogate for leukemic stem cell (LSC) frequency) [133]. In further support for its 
role in MLL-leukemogenesis, genetic silencing and/or chemical inhibition of LSD1 caused 
terminal differentiation of AML cell lines and significantly decreased the clonogenic 
potential of human cell lines, murine leukemias and primary samples with an MLL-
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rearrangement in vitro. These findings were also replicated in vivo, where LSD1 knockdown 
reduced LSC numbers and function, as measured by reduced engraftment capacity in 
secondary recipient mice. Functionally, the effects of LSD1 inhibition appear to be related to 
its ability to specifically modulate the levels of H3K4me2 at genes bound by the MLL-
translocation protein, suggesting that pharmacological inhibition of LSD1, could potentially 
be exploited therapeutically and might specifically alter the oncogenic transcriptional 
program of MLL-AF9 driven leukemias, whilst largely sparing overall global levels of 
H3K4me2. Another report demonstrated that the efficacy of LSD1 inhibition could also 
extend beyond MLL mutated leukemias, where it has been shown to increase the sensitivity 
of LSCs to the pro-differentiation effects of all-trans-retinoic acid (ATRA) treatment, 
irrespective of PML-RARA status. These findings suggest that LSD1 might contribute to AML 
pathogenesis through the inhibition of normal pro-differentiation programs in leukemic cells 
and proposes it as a novel therapeutic target in several subtypes of AML, especially if 
combined with ATRA. Mechanistically, LSD1 inhibition did not cause a generalized increase 
in H3K4me2, but instead specifically increased H3K4me2 levels and relative expression at 
myeloid-differentiation–associated genes[19]. The role of LSD1 might extend beyond AML 
as recent evidence suggest that LSD1 is also overexpressed in myeloproliferative neoplasms, 
myelodysplastic syndromes and in subsets of lymphoid malignancies, thus widening the 
range of hematological malignancies potentially targetable with LSD1 inhibitor 
therapy[134].
One caveat to the clinical development of LSD1 inhibitor is that its toxicity towards normal 
hematopoiesis has not been conclusively established, although normal cells appear less 
sensitive to LSD1 inhibition than leukemic cells[133]. A study on the role of LSD1 in normal 
hematopoiesis highlighted that terminal granulopoiesis, erythropoiesis and thrombopoiesis 
were inhibited upon LSD1 knockdown, however, these effects were reversible upon 
discontinuation of the inhibitor [136]. Moreover although LSD1 inhibition did not affect the 
overall frequency of colony forming cells in normal progenitors, it profoundly inhibited 
erythroid lineage differentiation resulting in severe anemia in the mouse models. These 
findings suggest that, despite a degree of toxicity, a therapeutic window is present for LSD1 
inhibition. This has recently prompted two phase 1 studies using compound GSK2879552 
(NCT02177812) and ORY-1001 (EudraCT 2013-002447-29) in patients with AML [Table 2]. 
The ORY-1001 trial is now complete and recently reported in preliminary form. LSD1 
inhibition demonstrated low toxicity and was well tolerated. Furthermore, there was  
evidence of blast differentiation and partial responses in almost 40% of evaluable patients, 
suggesting that further investigations are warranted[137].
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DYSREGULATED HISTONE ACETYLATION IN HEMATOLOGICAL MALIGNANCIES AND 
BROMODOMAIN CONTAINING PROTEINS AS THERAPEUTIC TARGETS
Histone acetylation is a highly dynamic process, controlled by two opposing classes of 
enzymes, lysine acetyltransferases (KATs) and histone deacetylases (HDACs). KATs transfer 
acetyl groups from the metabolic intermediate acetyl-CoA to the ε-aminogroup of lysine 
residues in histones and non-histone proteins. Histone lysine acetylation causes 
neutralization of a positive charge on histone proteins thus reducing their interaction with 
the negatively-charged DNA, leading to a more open chromatin state that is more 
permissive to the access of transcription factors and chromatin-associated protein. In 
addition, as reported for other DNA and histone modifications, the acetylated residues 
provide further docking sites for transcriptional regulators. Acetylation is considered as a 
modification that generally facilitates active transcription and several KATs are regarded as 
transcriptional co-activators. Conversely, HDACs remove acetyl groups from histones, 
leading to a more compacted chromatin state less permissive for transcription and are 
therefore generally regarded as transcriptional repressors[138]. Several different classes of 
both KATs and HDACs have been described and many of these have been found to be 
recurrently mutated in hematological malignancies [Table 1]. 
Histone Acetyl Transferases
Cyclic AMP-response element binding, binding protein, CBP (also known as CREBBP and 
KAT3A) and its paralogue the E1A binding protein p300, generally known as p300 (EP300 or 
KAT3B) are among the most commonly mutated KATs in hematological malignancies. The 
mutations are predominantly hemizygous and loss-of-function, mainly affect the 
acetyltransferase domain and its activity. They are very frequent in lymphoid malignancies, 
occurring in up to 40% of DLBL[139] and 60% of FL[140] but also occur with reduced 
frequency in B-cell ALL[141], T-cell ALL[142] and cutaneous T-cell lymphomas[143]. In 
myeloid malignancies CBP mutations are much less common and sporadic chromosomal 
translocation affecting CBP have also been described [12, 144-146]. CBP and p300 has been 
shown to act not only through their ability to acetylate histone (including H3K27Ac, H3K18Ac 
and H3K56Ac) and non-histone proteins but also through binding of other proteins [147]. 
They regulate several processes during homeostasis and development and the loss of Cbp in 
normal adult murine hematopoiesis causes gradual loss of phenotypic HSCs and 
differentiation defects that are exacerbated under replicative stress [148]. However the 
exact mechanism through which CBP contributes preferentially to lymphoid malignancies 
has only recently been investigated. Cbp loss, along with overexpression of Bcl2 in murine 
lymphoma models leads to focal depletion of H3K27 acetylation specifically at enhancers of 
genes involved in B-cell signaling and immune responses and their transcriptional silencing. 
Moreover Cbp loss-of-function appears to leave the same enhancer regions under the 
unopposed control of the BCL6/SMRT/HDAC3 transcriptional repressor complex. This 
suggests HDAC3 inhibition as a specific therapeutic vulnerability of CBP mutated lymphomas 
[149]. CBP mutations are often early mutations in mature lymphoid malignancies [150, 151] 
and recent work in murine models has shown that Cbp loss in early hematopoietic 
progenitors was also conducive to the development of lymphoid malignancies through the 
accumulation of a premalignant population. Cbp deleted premalignant lymphoid progenitors 
were susceptible to increased DNA damage and displayed an altered DNA-damage response 
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which in the context of increased exposure to physiological DNA-damage during lymphoid 
ontogeny could explain the high incidence of CBP mutations in mature lymphoid 
malignancies[152].
The role of CBP in the generation and maintenance of myeloid malignancies has also 
recently been investigated. The AML-specific translocation MOZ-TIF2, which occurs as a 
consequence of an inversion of chromosome 8, inv(8),[153] has been shown to recruit CBP 
to activate self-renewal transcriptional programs necessary for leukemic development and 
indeed MOZ-TIF2 was unable to transform murine progenitors in the absence of CBP [154, 
155]. More recently the acetyltransferase activity of p300 has also been shown to target the 
recurrent AML fusion protein RUNX1/RUNX1T1 (AML1-ETO) and play a key role in the self-
renewal and leukemogenic capacity of this recurrent translocation [156]. These findings have 
prompted interest in the development of small molecule KATs inhibitors [157] and 
preclinical studies have been published supporting their efficacy in inducing cell-cycle arrest 
and apoptosis in several AML subtypes. The effects of KATs inhibitors are particularly 
correlated with downregulation of genes involved in cell cycle and DNA repair and  
concomitant reduction in the acetylation levels at the promoters of the same genes  [155, 
158]. Overall the above data support a model whereby CBP acetyltransferase function is 
important for leukemic transformation and, similarly to other epigenetic modifiers, suggest 
that the role of CBP in the development of hematological malignancies is cell-context 
dependent, as it appears to act as both a tumor suppressor and an oncogene in specific 
cellular contexts. Clinical grade inhibitors of CBP enzymatic activity and bromodomain 
function (see below) are currently being developed and should be tested in clinical trials 
soon.
Histone Deacetylases
HDACs comprise a large number of proteins with the ability to deacetylate both histone and 
non-histone proteins. However, unlike many other epigenetic modifiers, recurrent mutations 
in HDACs are not observed in hematological malignancies. Instead, their role in the 
development of leukemias appears mostly secondary to their recruitment by specific 
oncoproteins to support repressive malignant gene expression programs. This is exemplified 
in acute promyelocytic leukemia (APML) by the ability of the PML-RARα and PZLF-RARα 
fusion proteins to act as aberrant transcriptional repressors, in part by recruiting histone 
deacetylases [159, 160]. HDAC inhibitors have entered the clinical arena and their role in 
treatment of cutaneous T-cell lymphoma, Hodgkin disease and MM is now more 
established[161-163]. However, their broader application to other hematological 
malignancies will likely require a better understanding of their role in malignant 
transformation and the development of specific rather than generic inhibitors[164]. 
Bromodomain Proteins
Acetylated lysines are recognized by proteins that contain specific motifs called 
bromodomains. Amongst this large family are the Bromodomain and Extra Terminal (BET) 
protein family of epigenetic readers that have emerged as important players in 
hematological malignancies and as promising therapeutic targets. BET proteins comprise the 
ubiquitously expressed BRD2, BRD3, BRD4 and the testes specific BRDT [165, 166]. These 
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protein contain tandem N-terminal bromodomains that bind acetylated lysine residues of 
histone (and non-histone) proteins and mediate effects ranging from histone modifications, 
chromatin remodeling and transcriptional activation via recruitment of other partner 
proteins [167]. BET proteins play an essential role in cellular homeostasis, as knockout 
mouse models are embryonically lethal [165, 168-171]. Moreover their role in promoting 
transcriptional dysregulation in many cancer types has been recently highlighted, with BRD4 
specifically identified as a key player in AML [22-25, 172-177]. In particular BRD4 is part of a 
protein complex including the positive transcription elongation factor b (P-TEFb) complex 
and the SEC and the polymerase-associated factor complex (PAFc), which are essential to the 
transforming ability of MLL-rearranged leukemias. As a result BRD4 appears to specifically 
recruit these complexes to active chromatin sites, which leads to the release of RNAPII from 
proximal promoter pausing and activation of oncogenic transcriptional programs. Inhibition 
of BRD4 binding to acetylated histone lysines via small molecule inhibitors was able to 
abrogate the activation of oncogenic MLL transcriptional programs and displayed 
remarkable efficacy in vitro and in vivo against MLL-fusion leukemias[Figure 3][22, 23]
Inhibition of BRD4 and other BET proteins has been shown to generate marked changes in 
gene expression that could not be fully explained by their ability to control transcriptional 
initiation and elongation. It has now become apparent that BRD4 and BET proteins also 
regulate enhancer function and in particular large clusters of enhancers, often called 
superenhancers, that drive the expression of developmentally important genes, including 
oncogenes such as BCL-2, IRF8 and c-MYC critical for the maintenance of the leukemic 
phenotype [172, 175]. The efficacy of BRD4 inhibitors also appears to extend beyond MLL-
rearranged leukemias, as small molecule BET inhibitors have shown promising results in in 
vitro and in vivo studies against nucleophosmin (NPM1), FLT3-ITD and DNMT3A mutated 
AML [174, 175, 177]. In NPM1c mutant AML, the cytosolic relocalization of both NPM1c and, 
via hetero-dimerization, WT NPM1 appears to abrogate an inhibitory interaction between 
WT NPM1 and BRD4, in turn allowing BRD4 to activate oncogenic transcriptional programs 
specific to NPM1c AML[175]. However, our understanding of specific mechanisms of action 
of BET inhibitors and of the requirement of BET proteins in other subtypes of AML remains 
poor. It is likely that beyond downregulating common transcriptional programs necessary for 
leukemia maintenance, BET inhibition might play a specific function in different subtypes 
through distinct interactions with driver mutations and their transcriptional partners. It is 
worth noting that the role of BET proteins and their therapeutic targeting has now been 
extended also to other hematological malignancies and specifically ALL, MM and non-
Hodgkin's lymphoma[24, 25, 178]. Common aberrant transcriptional programs are present in 
these malignancies often converging on the nexus of MYC activation. Indeed the efficacy of 
BET inhibition across these malignancies could be at least partially explained via 
downregulation of common effectors such as MYC and BCL2, although it is unlikely that the 
effects of BET inhibitors could be solely ascribed to this mechanism [172].
Although BET inhibitors have demonstrated promising efficacy as monotherapies in 
preclinical models, there is growing evidence that they might be even more effective in 
combination with other therapies. Promising results from combination treatment studies in 
which BET inhibitors were used together with FLT3 tyrosine kinase inhibitors [174], 
conventional cytostatic compounds (e.g. ARA-C) [173]and HDAC inhibitors [176]have been 
reported.  Combination with other epigenetic therapies has also been reported; a functional 
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interdependence between DOT1L and BRD4 in regulating transcription at highly expressed 
genes and in the proximity of superenhancers has been demonstrated. This suggests the 
possibility of combining DOT1L inhibitors with BRD4 inhibitors to achieve a more complete 
transcriptional repression in MLL rearranged leukemias [179]. However, a note of caution 
has been introduced by the modelling of BET inhibitor resistance in vitro and in vivo, that has 
suggested that the role of BRD4 in leukemia maintenance could become dispensable 
through activation of ancillary pathways such as WNT/βCatenin to maintain the critical gene 
programs and supporting the use of combined therapies to overcome this effect [180, 181].  
Based on this preclinical data, inhibition of BRD4/BET proteins has emerged as an exciting 
therapeutic option in the future therapy of AML and other hematological malignancies and 
several early phase studies using different BET inhibitors are currently underway [Table 2]. 
The most mature of these, utilizing the OTX015 inhibitor have recently reported for both 
AML and lymphoma/myeloma patients. In both cohorts, dose limiting toxicity, mostly 
hematological, identified an optimal dose of 80mg once daily on a schedule of 14 days on 
and 7 days off. This has now been carried forward to phase 2 studies, as a tolerated dose 
with a satisfactory safety profile. Although preliminary clinical activity was a secondary 
endpoint in both these trials, the number of objective responses were limited to around 10% 
of patients in both studies, thus suggesting that BET inhibition as a monotherapy might not 
be particularly effective in the subgroup of highly pretreated patients [182, 183]. However 
further clinical evaluation of BET inhibitors, particularly in the setting of combinations and 
earlier phases of disease, is warranted and ongoing with results eagerly awaited.
CONCLUSIONS
The description of the mutational spectrum in hematological malignancies by high-
throughput genetic analysis, combined with functional studies has highlighted epigenetic 
regulators as commonly mutated or dysregulated genes in a majority of hematological 
malignancies. Therefore altered epigenetic states have emerged as a hallmark of these blood 
cancers and have led to the development of targeted therapies aimed at eradicating 
malignant cells through the restoration of normal epigenetic and transcriptional states. 
Epigenetic regulators represent attractive therapeutic targets as they often have enzymatic 
activities or binding domains that lend themselves well to small molecule inhibition. 
However despite good preclinical evidence of efficacy and safety, only a few of these 
therapies have reached clinical development with encouraging results. It is therefore 
important to address the potential pitfalls that currently prevent us from taking full 
advantage of these rationally designed therapies.
One obvious problem is that often hematological malignancies, particularly the most 
advanced and aggressive such as AML, present a highly heterogeneous and complex clonal 
architecture which often evolves during the course of the disease and includes subclones 
possessing unique phenotypic and/or functional properties [34, 184, 185]. As such, a single 
therapy is unlikely to be able to completely target such complex diseases and the rational 
development of combination therapies based on sound preclinical studies is necessary to 
take full advantage of such therapies. Moreover resistance to epigenetic therapies has 
already been described in preclinical models [180, 181] and is likely to become a problem in 
the clinic when these agents are used as a single therapy. Another important issue is limiting 
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the toxicity of such therapies, particularly in combination. Epigenetic regulators are 
inevitably involved in normal processes within a cell and a rigorous understanding of the 
effects of inhibiting their function in such processes is necessary to design rational therapies 
capable of disrupting their malignant activity, while only minimally affecting their normal 
function. Perhaps particularly relevant in this respect, is a deeper understanding of the role 
of some epigenetic modifiers as both tumor suppressors and oncogenes in different cellular 
contexts, as is well demonstrated for both EZH2 and CBP. It is possible that extra caution 
needs to be exercised when developing these therapies in the clinic, possibly starting with 
very selected group of patients most likely to benefit from them. As an example, the 
experience thus far with IDH1/2 inhibitors, which arguably have been the most clinically 
successful of all epigenetic therapies, suggest that some of these therapies are likely to be 
beneficial only in highly specific subsets of patients, rather than across different patient 
subgroups, thus prompting the identification of sensitive genotypes and a more personalized 
approach in the development of epigenetic targeted therapies Another important area that 
will require better understanding is the role of epigenetic therapies on the immune system 
and in turn immune mediated tumor responses. Studies on patient samples and cell lines 
treated with demethylating agents suggest that these therapies might cause upregulation of 
PD-1 and other immune inhibitor ligands and receptors and that these effects might 
correlate with resistance to epigenetic therapies[186]. Conversely, studies on mouse models 
and cell lines representative of several hematological malignancies have highlighted a 
putative role of BRD4 inhibitors in downregulating the expression of the immune inhibitory 
molecule PD-L1. These effects might contribute to the efficacy of such therapies and 
potentially synergize with antibodies directly targeting the PD-1L/PD-1 axis[187]. The above 
findings further suggest that a deeper understanding of the broader effects of epigenetic 
therapies is required to fully take advantage of their antitumor effects and to best target 
their use towards a patient population most likely to benefit from them. 
Some practical aspects need also to be addressed to ensure a more rapid clinical 
development of the many epigenetic therapies that have been developed in recent years. 
One obvious problem is that most clinical trials tend to use these therapies as single agents 
in highly pretreated populations, thus decreasing the likelihood to observe significant 
efficacy. This strategy runs the risk that promising agents might be overlooked for further 
clinical development because of a lack of single-agent efficacy. A more realistic and likely 
successful strategy would be to expedite their use in combination with standard therapies or 
other targeted therapies based on rationally designed combinations, designed on the basis 
of preclinical studies. Another appealing strategy would be to use them in previously 
untreated patients, perhaps not suitable for standard therapies, to fully ascertain their 
therapeutic efficacy. Moreover some of these therapies lack clear cytotoxic effects in vitro 
and in vivo and require prolonged treatment to achieve a therapeutically discernible effect. 
In particular in more aggressive diseases, therefore, they might be better suited as a 
maintenance therapy following a debulking treatment from standard therapies, perhaps 
with their efficacy monitored by effects on gene expression, epigenetic marks and rationally 
designed biomarkers of response. 
In conclusion, despite the remarkable advances in our knowledge of the role of dysregulated 
epigenetics in hematological malignancies during the last decade, their translation into 
therapeutic advances for patients still requires significant efforts. Combining an even deeper 
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understanding of the epigenetic mechanisms leading to malignant transformation and the 
mechanisms of action of epigenetic inhibitors together with rationally designed clinical trials 
that aim to limit toxicity while enhancing efficacy of these therapies will be required if we 
are to fulfill the promise of such therapies in hematological malignancies. 
ACKNOWLEDGMENTS
We would like to thank all the members of the Huntly laboratory and our funders including 
the European Research Council, MRC, Bloodwise, the Kay Kendall Leukaemia Fund, the 
Wellcome Trust, the Cambridge NIHR Biomedical Research Centre, and core support grants 
to the Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute. We would 
like to thank Dr Mariella Vicinanza for her help in producing the figures in this manuscript. 
We apologize to those authors whose work we were unable to cite due to space constraints.
CONFLICT OF INTEREST STATEMENT
The authors declare that there are no conflicts of interest.
20
REFERENCES
1. Bryder, D., D.J. Rossi, and I.L. Weissman, Hematopoietic stem cells: the paradigmatic tissue-
specific stem cell. Am J Pathol, 2006. 169(2): p. 338-46.
2. Arber, D.A., et al., The 2016 revision to the World Health Organization classification of 
myeloid neoplasms and acute leukemia. Blood, 2016. 127(20): p. 2391-405.
3. Swerdlow, S.H., et al., The 2016 revision of the World Health Organization classification of 
lymphoid neoplasms. Blood, 2016. 127(20): p. 2375-90.
4. Berger, S.L., et al., An operational definition of epigenetics. Genes Dev, 2009. 23(7): p. 781-3.
5. Bednar, J., et al., Structure and Dynamics of a 197 bp Nucleosome in Complex with Linker 
Histone H1. Mol Cell, 2017. 66(3): p. 384-397 e8.
6. Cutter, A.R. and J.J. Hayes, Linker histones: novel insights into structure-specific recognition 
of the nucleosome. Biochem Cell Biol, 2017. 95(2): p. 171-178.
7. Dawson, M.A., T. Kouzarides, and B.J. Huntly, Targeting epigenetic readers in cancer. N Engl J 
Med, 2012. 367(7): p. 647-57.
8. Kouzarides, T., Chromatin modifications and their function. Cell, 2007. 128(4): p. 693-705.
9. Jones, P.A., Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat 
Rev Genet, 2012. 13(7): p. 484-92.
10. Goyama, S. and T. Kitamura, Epigenetics in normal and malignant hematopoiesis: An 
overview and update 2017. Cancer Sci, 2017. 108(4): p. 553-562.
11. Hu, D. and A. Shilatifard, Epigenetics of hematopoiesis and hematological malignancies. 
Genes Dev, 2016. 30(18): p. 2021-2041.
12. Cancer Genome Atlas Research, N., Genomic and epigenomic landscapes of adult de novo 
acute myeloid leukemia. N Engl J Med, 2013. 368(22): p. 2059-74.
13. Ntziachristos, P., et al., Genetic inactivation of the polycomb repressive complex 2 in T cell 
acute lymphoblastic leukemia. Nat Med, 2012. 18(2): p. 298-301.
14. Nikoloski, G., et al., Somatic mutations of the histone methyltransferase gene EZH2 in 
myelodysplastic syndromes. Nat Genet, 2010. 42(8): p. 665-7.
15. Morin, R.D., et al., Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-
cell lymphomas of germinal-center origin. Nat Genet, 2010. 42(2): p. 181-5.
16. Huether, R., et al., The landscape of somatic mutations in epigenetic regulators across 1,000 
paediatric cancer genomes. Nat Commun, 2014. 5: p. 3630.
17. Ernst, T., et al., Inactivating mutations of the histone methyltransferase gene EZH2 in 
myeloid disorders. Nat Genet, 2010. 42(8): p. 722-6.
18. Wang, F., et al., Targeted inhibition of mutant IDH2 in leukemia cells induces cellular 
differentiation. Science, 2013. 340(6132): p. 622-6.
19. Schenk, T., et al., Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-
retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med, 2012. 18(4): p. 
605-11.
20. Daigle, S.R., et al., Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood, 
2013. 122(6): p. 1017-25.
21. Daigle, S.R., et al., Selective killing of mixed lineage leukemia cells by a potent small-molecule 
DOT1L inhibitor. Cancer Cell, 2011. 20(1): p. 53-65.
22. Dawson, M.A., et al., Inhibition of BET recruitment to chromatin as an effective treatment for 
MLL-fusion leukaemia. Nature, 2011. 478(7370): p. 529-33.
23. Zuber, J., et al., RNAi screen identifies Brd4 as a therapeutic target in acute myeloid 
leukaemia. Nature, 2011. 478(7370): p. 524-8.
24. Delmore, J.E., et al., BET bromodomain inhibition as a therapeutic strategy to target c-Myc. 
Cell, 2011. 146(6): p. 904-17.
25. Mertz, J.A., et al., Targeting MYC dependence in cancer by inhibiting BET bromodomains. 
Proc Natl Acad Sci U S A, 2011. 108(40): p. 16669-74.
21
26. Li, E., Chromatin modification and epigenetic reprogramming in mammalian development. 
Nat Rev Genet, 2002. 3(9): p. 662-73.
27. Abdel-Wahab, O. and R.L. Levine, Mutations in epigenetic modifiers in the pathogenesis and 
therapy of acute myeloid leukemia. Blood, 2013. 121(18): p. 3563-72.
28. Pastor, W.A., L. Aravind, and A. Rao, TETonic shift: biological roles of TET proteins in DNA 
demethylation and transcription. Nat Rev Mol Cell Biol, 2013. 14(6): p. 341-56.
29. Ficz, G., et al., Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during 
differentiation. Nature, 2011. 473(7347): p. 398-402.
30. Takai, H., et al., 5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by 
recruiting the CHTOP-methylosome complex. Cell Rep, 2014. 9(1): p. 48-60.
31. Ley, T.J., et al., DNMT3A mutations in acute myeloid leukemia. N Engl J Med, 2010. 363(25): 
p. 2424-33.
32. Neumann, M., et al., Whole-exome sequencing in adult ETP-ALL reveals a high rate of 
DNMT3A mutations. Blood, 2013. 121(23): p. 4749-52.
33. Couronne, L., C. Bastard, and O.A. Bernard, TET2 and DNMT3A mutations in human T-cell 
lymphoma. N Engl J Med, 2012. 366(1): p. 95-6.
34. Shlush, L.I., et al., Identification of pre-leukaemic haematopoietic stem cells in acute 
leukaemia. Nature, 2014. 506(7488): p. 328-33.
35. Genovese, G., et al., Clonal hematopoiesis and blood-cancer risk inferred from blood DNA 
sequence. N Engl J Med, 2014. 371(26): p. 2477-87.
36. Jaiswal, S., et al., Age-related clonal hematopoiesis associated with adverse outcomes. N Engl 
J Med, 2014. 371(26): p. 2488-98.
37. Russler-Germain, D.A., et al., The R882H DNMT3A mutation associated with AML dominantly 
inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell, 2014. 
25(4): p. 442-54.
38. Yang, L., R. Rau, and M.A. Goodell, DNMT3A in haematological malignancies. Nat Rev 
Cancer, 2015. 15(3): p. 152-65.
39. Challen, G.A., et al., Dnmt3a is essential for hematopoietic stem cell differentiation. Nat 
Genet, 2011. 44(1): p. 23-31.
40. Gozdecka, M., et al., Functional and Molecular Consequences of the Dnmt3aR882H Mutation 
in Acute Myeloid Leukaemia. Blood, 2015. 126(23).
41. Guryanova, O.A., et al., DNMT3A mutations promote anthracycline resistance in acute 
myeloid leukemia via impaired nucleosome remodeling. Nat Med, 2016. 22(12): p. 1488-
1495.
42. Jeong, M., et al., Large conserved domains of low DNA methylation maintained by Dnmt3a. 
Nat Genet, 2014. 46(1): p. 17-23.
43. Solary, E., et al., The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and 
hematopoietic diseases. Leukemia, 2014. 28(3): p. 485-96.
44. Abdel-Wahab, O., et al., Genetic characterization of TET1, TET2, and TET3 alterations in 
myeloid malignancies. Blood, 2009. 114(1): p. 144-7.
45. Quivoron, C., et al., TET2 inactivation results in pleiotropic hematopoietic abnormalities in 
mouse and is a recurrent event during human lymphomagenesis. Cancer Cell, 2011. 20(1): p. 
25-38.
46. Shih, A.H., et al., Mutational cooperativity linked to combinatorial epigenetic gain of function 
in acute myeloid leukemia. Cancer Cell, 2015. 27(4): p. 502-15.
47. Dang, L. and S.M. Su, Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From 
Basic Discovery to Therapeutics Development. Annu Rev Biochem, 2017. 86: p. 305-331.
48. Reitman, Z.J. and H. Yan, Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations 
at a crossroads of cellular metabolism. J Natl Cancer Inst, 2010. 102(13): p. 932-41.
22
49. Chotirat, S., et al., Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) 
metabolic genes and additional genetic mutations in newly diagnosed acute myeloid 
leukemia patients. J Hematol Oncol, 2012. 5: p. 5.
50. Marcucci, G., et al., IDH1 and IDH2 gene mutations identify novel molecular subsets within de 
novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 
J Clin Oncol, 2010. 28(14): p. 2348-55.
51. Mardis, E.R., et al., Recurring mutations found by sequencing an acute myeloid leukemia 
genome. N Engl J Med, 2009. 361(11): p. 1058-66.
52. Odejide, O., et al., A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. 
Blood, 2014. 123(9): p. 1293-6.
53. Cairns, R.A., et al., IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. 
Blood, 2012. 119(8): p. 1901-3.
54. Tefferi, A., et al., IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or 
blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 2010. 
24(7): p. 1302-9.
55. Kosmider, O., et al., Mutations of IDH1 and IDH2 genes in early and accelerated phases of 
myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia, 2010. 24(5): 
p. 1094-6.
56. Parsons, D.W., et al., An integrated genomic analysis of human glioblastoma multiforme. 
Science, 2008. 321(5897): p. 1807-12.
57. Ward, P.S., et al., The common feature of leukemia-associated IDH1 and IDH2 mutations is a 
neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer 
Cell, 2010. 17(3): p. 225-34.
58. Chowdhury, R., et al., The oncometabolite 2-hydroxyglutarate inhibits histone lysine 
demethylases. EMBO Rep, 2011. 12(5): p. 463-9.
59. Xu, W., et al., Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-
ketoglutarate-dependent dioxygenases. Cancer Cell, 2011. 19(1): p. 17-30.
60. Figueroa, M.E., et al., Leukemic IDH1 and IDH2 mutations result in a hypermethylation 
phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 
2010. 18(6): p. 553-67.
61. Lu, C., et al., IDH mutation impairs histone demethylation and results in a block to cell 
differentiation. Nature, 2012. 483(7390): p. 474-8.
62. Boissel, N., et al., Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 
mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association 
group. J Clin Oncol, 2010. 28(23): p. 3717-23.
63. Green, C.L., et al., The prognostic significance of IDH2 mutations in AML depends on the 
location of the mutation. Blood, 2011. 118(2): p. 409-12.
64. Koszarska, M., et al., Type and location of isocitrate dehydrogenase mutations influence 
clinical characteristics and disease outcome of acute myeloid leukemia. Leuk Lymphoma, 
2013. 54(5): p. 1028-35.
65. Paschka, P., et al., IDH1 and IDH2 mutations are frequent genetic alterations in acute 
myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid 
leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol, 2010. 
28(22): p. 3636-43.
66. Thol, F., et al., Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid 
leukemia. Blood, 2010. 116(4): p. 614-6.
67. Losman, J.A., et al., (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its 
effects are reversible. Science, 2013. 339(6127): p. 1621-5.
68. Sasaki, M., et al., IDH1(R132H) mutation increases murine haematopoietic progenitors and 
alters epigenetics. Nature, 2012. 488(7413): p. 656-9.
23
69. Chaturvedi, A., et al., Mutant IDH1 promotes leukemogenesis in vivo and can be specifically 
targeted in human AML. Blood, 2013. 122(16): p. 2877-87.
70. Chaturvedi, A., et al., A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and 
Prolongs Survival in a Mouse Model of Leukemia. Blood, 2014. 124(21): p. Abstract 3598.
71. Irwin, J.J., et al., ZINC: a free tool to discover chemistry for biology. J Chem Inf Model, 2012. 
52(7): p. 1757-68.
72. Kernytsky, A., et al., IDH2 mutation induced histone and DNA hypermethylation is 
progressively reversed by small molecule inhibition. Blood, 2014.
73. Stein, E.M., et al., Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. 
Blood, 2017.
74. Amatangelo, M.D., et al., Enasidenib induces acute myeloid leukemia cell differentiation to 
promote clinical response. Blood, 2017.
75. Allis, C.D., et al., New nomenclature for chromatin-modifying enzymes. Cell, 2007. 131(4): p. 
633-6.
76. Hojfeldt, J.W., K. Agger, and K. Helin, Histone lysine demethylases as targets for anticancer 
therapy. Nat Rev Drug Discov, 2013. 12(12): p. 917-30.
77. Barski, A., et al., High-resolution profiling of histone methylations in the human genome. Cell, 
2007. 129(4): p. 823-37.
78. Zhang, J., et al., The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. 
Nature, 2012. 481(7380): p. 157-63.
79. Yap, D.B., et al., Somatic mutations at EZH2 Y641 act dominantly through a mechanism of 
selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood, 2011. 
117(8): p. 2451-9.
80. Morera, L., M. Lubbert, and M. Jung, Targeting histone methyltransferases and 
demethylases in clinical trials for cancer therapy. Clin Epigenetics, 2016. 8: p. 57.
81. Morin, R.D., et al., Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. 
Nature, 2011. 476(7360): p. 298-303.
82. Pasqualucci, L., et al., Analysis of the coding genome of diffuse large B-cell lymphoma. Nat 
Genet, 2011. 43(9): p. 830-7.
83. Zhang, J., et al., Disruption of KMT2D perturbs germinal center B cell development and 
promotes lymphomagenesis. Nat Med, 2015. 21(10): p. 1190-8.
84. Ernst, P., et al., An Mll-dependent Hox program drives hematopoietic progenitor expansion. 
Curr Biol, 2004. 14(22): p. 2063-9.
85. Hess, J.L., et al., Defects in yolk sac hematopoiesis in Mll-null embryos. Blood, 1997. 90(5): p. 
1799-806.
86. McMahon, K.A., et al., Mll has a critical role in fetal and adult hematopoietic stem cell self-
renewal. Cell Stem Cell, 2007. 1(3): p. 338-45.
87. Jude, C.D., et al., Unique and independent roles for MLL in adult hematopoietic stem cells 
and progenitors. Cell Stem Cell, 2007. 1(3): p. 324-37.
88. De Braekeleer, M., et al., The MLL gene and translocations involving chromosomal band 
11q23 in acute leukemia. Anticancer Res, 2005. 25(3B): p. 1931-44.
89. Krivtsov, A.V. and S.A. Armstrong, MLL translocations, histone modifications and leukaemia 
stem-cell development. Nat Rev Cancer, 2007. 7(11): p. 823-33.
90. Meyer, C., et al., The MLL recombinome of acute leukemias in 2013. Leukemia, 2013. 27(11): 
p. 2165-76.
91. Luo, Z., C. Lin, and A. Shilatifard, The super elongation complex (SEC) family in transcriptional 
control. Nat Rev Mol Cell Biol, 2012. 13(9): p. 543-7.
92. Nguyen, A.T. and Y. Zhang, The diverse functions of Dot1 and H3K79 methylation. Genes Dev, 
2011. 25(13): p. 1345-58.
93. Kim, W., et al., Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) 
inhibits cell proliferation. J Biol Chem, 2012. 287(8): p. 5588-99.
24
94. Tatum, D. and S. Li, Evidence that the histone methyltransferase Dot1 mediates global 
genomic repair by methylating histone H3 on lysine 79. J Biol Chem, 2011. 286(20): p. 17530-
5.
95. Kim, S.K., et al., Human histone H3K79 methyltransferase DOT1L protein [corrected] binds 
actively transcribing RNA polymerase II to regulate gene expression. J Biol Chem, 2012. 
287(47): p. 39698-709.
96. Feng, Y., et al., Early mammalian erythropoiesis requires the Dot1L methyltransferase. Blood, 
2010. 116(22): p. 4483-91.
97. Bernt, K.M., et al., MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by 
DOT1L. Cancer Cell, 2011. 20(1): p. 66-78.
98. Chang, M.J., et al., Histone H3 lysine 79 methyltransferase Dot1 is required for 
immortalization by MLL oncogenes. Cancer Res, 2010. 70(24): p. 10234-42.
99. Jo, S.Y., et al., Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis 
by MLL translocation. Blood, 2011. 117(18): p. 4759-68.
100. Nguyen, A.T., et al., DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated 
leukemogenesis. Blood, 2011. 117(25): p. 6912-22.
101. Deshpande, A.J., et al., AF10 Regulates Progressive H3K79 Methylation and HOX Gene 
Expression in Diverse AML Subtypes. Cancer Cell, 2014. 26(6): p. 896-908.
102. Mueller, D., et al., A role for the MLL fusion partner ENL in transcriptional elongation and 
chromatin modification. Blood, 2007. 110(13): p. 4445-54.
103. Okada, Y., et al., hDOT1L links histone methylation to leukemogenesis. Cell, 2005. 121(2): p. 
167-78.
104. Zhang, W., et al., Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and 
repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem, 2006. 281(26): p. 
18059-68.
105. Kuhn, M.W., et al., MLL partial tandem duplication leukemia cells are sensitive to small 
molecule DOT1L inhibition. Haematologica, 2015. 100(5): p. e190-3.
106. Rau, R.E., et al., DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute 
myeloid leukemia. Blood, 2016. 128(7): p. 971-81.
107. Sarkaria, S.M., et al., Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations 
respond to a DOT1L inhibitor in vitro. Leukemia, 2014. 28(12): p. 2403-6.
108. Kuhn, M.W., et al., Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression 
in NPM1 Mutant Leukemia. Cancer Discov, 2016. 6(10): p. 1166-1181.
109. Stein, E.M., et al., The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory 
Patients with MLL-Rearranged Leukemia. Blood, 2014. 124(21): p. Abstract 387.
110. Shukla, N., et al., Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-
5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia. Blood, 2016. 128(22): 
p. 2780.
111. Sashida, G. and A. Iwama, Multifaceted role of the polycomb-group gene EZH2 in 
hematological malignancies. Int J Hematol, 2017. 105(1): p. 23-30.
112. Xie, H., et al., Polycomb repressive complex 2 regulates normal hematopoietic stem cell 
function in a developmental-stage-specific manner. Cell Stem Cell, 2014. 14(1): p. 68-80.
113. Souroullas, G.P., et al., An oncogenic Ezh2 mutation induces tumors through global 
redistribution of histone 3 lysine 27 trimethylation. Nat Med, 2016. 22(6): p. 632-40.
114. Beguelin, W., et al., EZH2 is required for germinal center formation and somatic EZH2 
mutations promote lymphoid transformation. Cancer Cell, 2013. 23(5): p. 677-92.
115. Berg, T., et al., A transgenic mouse model demonstrating the oncogenic role of mutations in 
the polycomb-group gene EZH2 in lymphomagenesis. Blood, 2014. 123(25): p. 3914-24.
116. Guglielmelli, P., et al., EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 
2011. 118(19): p. 5227-34.
25
117. Danis, E., et al., Ezh2 Controls an Early Hematopoietic Program and Growth and Survival 
Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. Cell Rep, 2016. 14(8): p. 
1953-65.
118. Mochizuki-Kashio, M., et al., Ezh2 loss in hematopoietic stem cells predisposes mice to 
develop heterogeneous malignancies in an Ezh1-dependent manner. Blood, 2015. 126(10): p. 
1172-83.
119. Sashida, G., et al., The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes 
tumor-initiating cells to bromodomain inhibition. J Exp Med, 2016. 213(8): p. 1459-77.
120. Shimizu, T., et al., Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative 
neoplasms and promoting myelofibrosis. J Exp Med, 2016. 213(8): p. 1479-96.
121. Yang, Y., et al., Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis 
in a mouse model of myeloproliferative neoplasm. Blood, 2016. 127(26): p. 3410-23.
122. Scott, M.T., et al., Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 
and Tyrosine Kinase Inhibition. Cancer Discov, 2016. 6(11): p. 1248-1257.
123. Xie, H., et al., Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group 
Protein EZH2. Cancer Discov, 2016. 6(11): p. 1237-1247.
124. Tanaka, S., et al., Ezh2 augments leukemogenicity by reinforcing differentiation blockage in 
acute myeloid leukemia. Blood, 2012. 120(5): p. 1107-17.
125. Neff, T., et al., Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl 
Acad Sci U S A, 2012. 109(13): p. 5028-33.
126. Sashida, G., et al., Ezh2 loss promotes development of myelodysplastic syndrome but 
attenuates its predisposition to leukaemic transformation. Nat Commun, 2014. 5: p. 4177.
127. Gollner, S., et al., Loss of the histone methyltransferase EZH2 induces resistance to multiple 
drugs in acute myeloid leukemia. Nat Med, 2017. 23(1): p. 69-78.
128. Yap, T.A., et al., A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) 
Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), 
Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors 
and Multiple Myeloma (MM). Blood, 2016. 128(22): p. 4203.
129. Shi, Y., et al., Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. 
Cell, 2004. 119(7): p. 941-53.
130. Huang, J., et al., p53 is regulated by the lysine demethylase LSD1. Nature, 2007. 449(7158): p. 
105-8.
131. Rudolph, T., S. Beuch, and G. Reuter, Lysine-specific histone demethylase LSD1 and the 
dynamic control of chromatin. Biol Chem, 2013. 394(8): p. 1019-28.
132. Metzger, E., et al., LSD1 demethylates repressive histone marks to promote androgen-
receptor-dependent transcription. Nature, 2005. 437(7057): p. 436-9.
133. Lynch, J.T., W.J. Harris, and T.C. Somervaille, LSD1 inhibition: a therapeutic strategy in 
cancer? Expert Opin Ther Targets, 2012. 16(12): p. 1239-49.
134. Niebel, D., et al., Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid 
neoplasms. Blood, 2014. 124(1): p. 151-2.
135. Nakamura, T., et al., ALL-1 is a histone methyltransferase that assembles a supercomplex of 
proteins involved in transcriptional regulation. Mol Cell, 2002. 10(5): p. 1119-28.
136. Sprussel, A., et al., Lysine-specific demethylase 1 restricts hematopoietic progenitor 
proliferation and is essential for terminal differentiation. Leukemia, 2012. 26(9): p. 2039-51.
137. Somervaille, T., et al., Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary 
Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone 
Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study. Blood, 
2016. 128(22).
138. Shahbazian, M.D. and M. Grunstein, Functions of site-specific histone acetylation and 
deacetylation. Annu Rev Biochem, 2007. 76: p. 75-100.
26
139. Pasqualucci, L., et al., Inactivating mutations of acetyltransferase genes in B-cell lymphoma. 
Nature. 471(7337): p. 189-95.
140. Okosun, J., et al., Integrated genomic analysis identifies recurrent mutations and evolution 
patterns driving the initiation and progression of follicular lymphoma. Nat Genet, 2014. 
46(2): p. 176-81.
141. Mullighan, C.G., et al., CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 
471(7337): p. 235-9.
142. Vicente, C., et al., Targeted sequencing identifies associations between IL7R-JAK mutations 
and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica, 2015. 
100(10): p. 1301-10.
143. da Silva Almeida, A.C., et al., The mutational landscape of cutaneous T cell lymphoma and 
Sezary syndrome. Nat Genet, 2015. 47(12): p. 1465-70.
144. Papaemmanuil, E., et al., Clinical and biological implications of driver mutations in 
myelodysplastic syndromes. Blood, 2013. 122(22): p. 3616-27; quiz 3699.
145. Sobulo, O.M., et al., MLL is fused to CBP, a histone acetyltransferase, in therapy-related 
acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A, 1997. 94(16): p. 
8732-7.
146. Taki, T., et al., The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the 
MLL gene to the CBP gene. Blood, 1997. 89(11): p. 3945-50.
147. Blobel, G.A., CREB-binding protein and p300: molecular integrators of hematopoietic 
transcription. Blood, 2000. 95(3): p. 745-55.
148. Chan, W.I., et al., The transcriptional coactivator Cbp regulates self-renewal and 
differentiation in adult hematopoietic stem cells. Mol Cell Biol, 2011. 31(24): p. 5046-60.
149. Jiang, Y., et al., CREBBP Inactivation Promotes the Development of HDAC3-Dependent 
Lymphomas. Cancer Discov, 2017. 7(1): p. 38-53.
150. Green, M.R., et al., Mutations in early follicular lymphoma progenitors are associated with 
suppressed antigen presentation. Proc Natl Acad Sci U S A, 2015. 112(10): p. E1116-25.
151. Green, M.R., et al., Hierarchy in somatic mutations arising during genomic evolution and 
progression of follicular lymphoma. Blood, 2013. 121(9): p. 1604-11.
152. Huntly, B.J.P., et al., Early Loss of CREBBP Confers Malignant Stem Cell Properties on 
Lymphoid Progenitors Blood, 2016. 128(22): p. 460.
153. Carapeti, M., et al., A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in 
acute myeloid leukemia. Blood, 1998. 91(9): p. 3127-33.
154. Deguchi, K., et al., MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome 
binding motif and TIF2-mediated recruitment of CBP. Cancer Cell, 2003. 3(3): p. 259-71.
155. Giotopoulos, G., et al., The epigenetic regulators CBP and p300 facilitate leukemogenesis and 
represent therapeutic targets in acute myeloid leukemia. Oncogene, 2016. 35(3): p. 279-89.
156. Wang, L., et al., The leukemogenicity of AML1-ETO is dependent on site-specific lysine 
acetylation. Science, 2011. 333(6043): p. 765-9.
157. Bowers, E.M., et al., Virtual ligand screening of the p300/CBP histone acetyltransferase: 
identification of a selective small molecule inhibitor. Chem Biol, 2010. 17(5): p. 471-82.
158. Gao, X.N., et al., A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and 
apoptosis selectively in AML1-ETO-positive AML cells. PLoS One, 2013. 8(2): p. e55481.
159. He, L.Z., et al., Histone deacetylase inhibitors induce remission in transgenic models of 
therapy-resistant acute promyelocytic leukemia. J Clin Invest, 2001. 108(9): p. 1321-30.
160. He, L.Z., et al., Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors 
determine differential responses to RA in APL. Nat Genet, 1998. 18(2): p. 126-35.
161. Younes, A., et al., Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma 
after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol, 2012. 
30(18): p. 2197-203.
27
162. Lemoine, M., et al., The pan-deacetylase inhibitor panobinostat induces cell death and 
synergizes with everolimus in Hodgkin lymphoma cell lines. Blood, 2012. 119(17): p. 4017-25.
163. San-Miguel, J.F., et al., Panobinostat plus bortezomib and dexamethasone versus placebo 
plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory 
multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol, 
2014. 15(11): p. 1195-206.
164. Fong, C.Y., J. Morison, and M.A. Dawson, Epigenetics in the hematologic malignancies. 
Haematologica, 2014. 99(12): p. 1772-83.
165. Wu, S.Y. and C.M. Chiang, The double bromodomain-containing chromatin adaptor Brd4 and 
transcriptional regulation. J Biol Chem, 2007. 282(18): p. 13141-5.
166. Pivot-Pajot, C., et al., Acetylation-dependent chromatin reorganization by BRDT, a testis-
specific bromodomain-containing protein. Mol Cell Biol, 2003. 23(15): p. 5354-65.
167. Taverna, S.D., et al., How chromatin-binding modules interpret histone modifications: lessons 
from professional pocket pickers. Nat Struct Mol Biol, 2007. 14(11): p. 1025-40.
168. Dey, A., et al., The double bromodomain protein Brd4 binds to acetylated chromatin during 
interphase and mitosis. Proc Natl Acad Sci U S A, 2003. 100(15): p. 8758-63.
169. Kanno, T., et al., Selective recognition of acetylated histones by bromodomain proteins 
visualized in living cells. Mol Cell, 2004. 13(1): p. 33-43.
170. Houzelstein, D., et al., Growth and early postimplantation defects in mice deficient for the 
bromodomain-containing protein Brd4. Mol Cell Biol, 2002. 22(11): p. 3794-802.
171. Shang, E., et al., Double bromodomain-containing gene Brd2 is essential for embryonic 
development in mouse. Dev Dyn, 2009. 238(4): p. 908-17.
172. Loven, J., et al., Selective inhibition of tumor oncogenes by disruption of super-enhancers. 
Cell, 2013. 153(2): p. 320-34.
173. Herrmann, H., et al., Small-molecule inhibition of BRD4 as a new potent approach to 
eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget, 
2012. 3(12): p. 1588-99.
174. Fiskus, W., et al., BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase 
inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol 
Cancer Ther, 2014. 13(10): p. 2315-27.
175. Dawson, M.A., et al., Recurrent mutations, including NPM1c, activate a BRD4-dependent 
core transcriptional program in acute myeloid leukemia. Leukemia, 2014. 28(2): p. 311-20.
176. Fiskus, W., et al., Highly active combination of BRD4 antagonist and histone deacetylase 
inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther, 2014. 13(5): p. 
1142-54.
177. Stewart, H.J., et al., BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is 
implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med, 2013. 2(6): p. 826-
35.
178. Ott, C.J., et al., BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute 
lymphoblastic leukemia. Blood, 2012. 120(14): p. 2843-52.
179. Gilan, O., et al., Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct 
Mol Biol, 2016. 23(7): p. 673-81.
180. Fong, C.Y., et al., BET inhibitor resistance emerges from leukaemia stem cells. Nature, 2015. 
525(7570): p. 538-42.
181. Rathert, P., et al., Transcriptional plasticity promotes primary and acquired resistance to BET 
inhibition. Nature, 2015. 525(7570): p. 543-7.
182. Amorim, S., et al., Bromodomain inhibitor OTX015 in patients with lymphoma or multiple 
myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol, 
2016. 3(4): p. e196-204.
183. Berthon, C., et al., Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-
escalation, phase 1 study. Lancet Haematol, 2016. 3(4): p. e186-95.
28
184. Ding, L., et al., Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-
genome sequencing. Nature, 2012. 481(7382): p. 506-10.
185. Klco, J.M., et al., Functional heterogeneity of genetically defined subclones in acute myeloid 
leukemia. Cancer Cell, 2014. 25(3): p. 379-92.
186. Yang, H., et al., Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is 
enhanced by treatment with hypomethylating agents. Leukemia, 2014. 28(6): p. 1280-8.
187. Hogg, S.J., et al., BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate 
Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep, 2017. 18(9): p. 2162-2174.
Table 1. Epigenetic regulators most recurrently mutated in hematological malignancies
EPIGENETIC REGULATOR MUTATION TYPE DISEASE 
EPIGENETIC WRITERS
DNA METHYLTRANSFERASE
DNMT3A*
DNA DIOXYGENASES
TET2*
HISTONE METHYLTRANSFERASE
KMT2A (MLL1)
KMT2D (MLL2)
KMT2C (MLL3)
KMT6 (EZH2)
HISTONE ACETYLTRANSFERASE
KAT3A (CBP)
KAT3B (EP300)
KAT6A (MOZ)
KAT6B (MORF)
Point mutation
Indel
Point mutation
Indel
Translocation (MLL-X)
Partial Tandem Duplication
Point mutation
Point mutation
Point mutation
Indel
Translocation (MLL-CBP, MOZ-CBP)
Point mutation
Translocation (MOZ-EP300)
Point mutation
Translocation (MOZ-CBP, MOZ-
TIF2)
Translocation (MORF-CBP)
AML/MDS/MPN/TCL
AML/MPN/MDS/TCL
AML/ALL
AML
BCL
BCL/AML
BCL
MPN/MDS/AML
AML
BCL
AML
BCL
AML
AML
EPIGENETIC ERASERS
HISTONE DEMETHYLASES
KDM5A (JARID1A)
KDM6A (UTX)
Translocation (NUP98-JARID1A)
Point mutation
AML
TCL/AML
METABOLIC ENZYMES
ISOCITRATE DEHYDROGENASE
IDH1*
IDH2*
Point mutation
Point mutation
AML/MDS/MPN/TCL
AML/MDS/MPN/TCL
MEMBERS OF EPIGENETIC 
REGULATORS PROTEIN COMPLEXES
ASXL1* Point mutation AML/MDS/MPN
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BCL, B-cell lymphomas; MPN, 
myeloproliferative neoplasms; MDS, myelodysplastic syndromes; TCL, T-cell lymphoma/leukemia;
CBP, CREB binding protein; EZH2, enhancer of zest homolog 2; IDH, isocitrate dehydrogenase; JARID1A, Jumonji 
AT-rich interactive domain 1A; MLL, mixed lineage leukemia; MORF, MOZ-related factors; MOZ, monocytic 
leukemia zinc finger; NSD, nuclear receptor binding SET-Domain ; NUP98, nucleoporin 98kDa; TET, ten-eleven 
translocation; TIF (NCOA2), nuclear receptor coactivator 2; UTX, ubiquitously transcribed tetratricopeptide 
repeat, X chromosome; ASXL1, additional sex comb-like 1 
* These mutations are also encountered recurrently in clonal hematopoiesis
Table 2. Main clinical trials of novel epigenetic therapies in hematological malignancies as of May 2017*
EPIGENETIC TARGET TRIAL NUMBER DRUG PHASE DISEASE STATUS
Histone Demethylase 
inhibitors
LSD1 NCT02177812
EudraCT 2013-002447-
29
GSK2879552
ORY-1001
1
1
AML
AML/ALL
Recruiting
Completed
Histone Methylase 
inhibitors
DOT1L
EZH2
NCT01684150
NCT02141828 
NCT02395601
NCT02082977
NCT01897571
EPZ-5676
EPZ-5676
CPI-1205
GSK2816126
Tazemetostat
1
1
1
1/2
1/2
AML/ALL
AML/ALL-
PEDS
BCL
BCL/MM
BCL
Recruiting1
Completed
Recruiting
Recruiting
Recruiting
Bromodomain inhibitors
BET proteins NCT02158858
NCT01943851
NCT01713582
NCT02308761
CPI-0610
GSK525762
OTX015
TEN-010
1
1/2
1
1/2
MNP
HN
HN
MNP
Recruiting
Recruiting
Completed/
Reported
Recruiting
Metabolic enyzmes 
inhibitors
IDH1
IDH2
NCT02074839
NCT01915498
NCT02577406
NCT02273739
AG-120
AG-221
AG-221
AG-221
1
1/2
3
1/2
IDH1mut HN
IDH2mut HN
IDH2mut AML
IDH2mut TCL
Recruiting
Ongoing/
Reported
Recruiting
Completed
*only trials involving the targets discussed in the review are presented; 1 only recruiting for extension phase
BET, bromodomain and extra-terminal domain family; DOT1L, disruptor of telomeric silencing 1-like; IDH, 
isocitrate dehydrogenase; LSD, lysine specific demethylase; EZH2, Enhancer of zeste homolog 2;  AML, acute 
myeloid leukemia; ALL, acute lymphoblastic leukemia; PEDS, pediatric;  BCL, B-cell lymphomas; MM, Multiple 
myeloma; MNP, myeloid neoplasms; HN, hematological neoplasms; TCL, T-cell lymphoma;


Figure Legends
Figure 1.  Diagram of different types of epigenetic regulators
Schematic of epigenetic regulators involved in histone methylation and acetylation are 
respectively shown in panel A and B. The epigenetic machinery consists of three classes of 
proteins, writers, readers and erasers. Epigenetic writers are enzymes catalyzing covalent 
histones modifications such as methylation (Me) or acetylation (Ac) of specific lysine residues. 
Examples of such enzymes are the mehyltransferases, EZH2 and the acetyltransferases, CBP. 
Conversely epigenetic erasers, such as the demethylase LSD1 and multiple histone 
deacetylases (HDAC), catalytically remove these histone modifications. Epigenetic readers are 
proteins containing highly specialized domains, such as plant homeodomain (PHD) fingers and 
bromodomains (BRD) which recognize and specifically bind to unique histone modifications, 
in this case lysine methylation and acetylation respectively. Manipulating these regulatory 
processes forms the basis of therapeutic targeting the epigenome.
Figure 2. Mechanism of action of IDH1/2 inhibitors
(A)  Isocitrate dehydrogenase (IDH) 1 and 2 mutations give rise to neomorphic proteins that 
bind with increased affinity to the normal IDH product α-ketoglutarate and subsequently lead 
to its further reduction to 2-hydroxyglutarate (2-HG). The accumulation of 2-HG in leukemic 
cells inhibits dioxygenase enzymes that require α-ketoglutarate, including the TET family of 
DNA dioxygenase and the Jumonji-C (JmjC) domain-containing family of histone lysine 
demethylases. Inhibition of these enzymes results in aberrant DNA and histone methylation 
patterns that direct altered transcriptional programs, causing a block in cellular 
differentiation. (B) The highly specific IDH1 and 2 inhibitors (AG120 and AG221, shown) block 
the neomorphic activity of the mutant proteins specifically, restoring normal levels of 2-HG 
and DNA and histone methylation patterns within the cell. This in turn leads to reactivation 
of transcriptional programs leading to normal cellular differentiation 
Figure 3. Model for the mechanism of action of DOT1L and BET proteins inhibitors in MLL 
fusion leukemias
(A) The MLL fusion protein are composed by the aminoterminal domain of the MLL protein 
and several translocation partners that are usually members of multi-subunit protein 
complexes involved in chromatin remodelling and transcriptional elongation. The 
aminoterminal domain of MLL proteins, which is uniformly preserved in MLL fusions, 
physically interacts with the polymerase-associated factor complex (PAFc) while its most 
frequent fusion partners (AF4, AF9, AF10, ENL, ELL) are part of either the super elongation 
complex (SEC) or disruptor of telomeric silencing 1-like (DOT1L)-containing complex. The SEC 
also includes the positive transcription elongation factor-b (PTEFb), composed of CDK9 and 
cyclin T1 or T2, and this complex phosphorylates (P) RNA polymerase II (RNA POL II) facilitating 
transcriptional elongation. BRD4 is a BET protein known to physically interact with both PAF 
and SEC-PTEFb and to bind acetyl lysine residues (Ac) on multiple histones. As a result BRD4 
specifically recruits the SEC-PTEFb complex to active chromatin, leading to transcription of 
MLL fusion target genes and activation of an oncogenic transcriptional program. The lysine 
methylase DOT1L is also known to interact with several fusion partners of MLL translocations, 
such as AF4, AF9, AF10 and ENL. The interaction of DOT1L with AF9 leads to its aberrant 
recruitment to MLL-AF9 fusion target genes. At these target sites, DOT1L methylates lysine 
79 of histone 3 (H3K79) using S-(5`-adenosyl)-l-methionine (SAM) as a donor of methyl (Me) 
groups.  H3K79 methylation is known to be an activating mark which facilitates transcription 
of MLL target genes. (B) EPZ-5676 is a SAM mimetic which inhibits the methylase activity of 
DOT1L, reduces H3K79 methylation at MLL-AF9 target genes and leads to transcriptional 
suppression of the MLL-AF9 oncogenic program. Similarly, bromodomain inhibitors (BRD INH) 
inhibit the interaction of BRD4 with acetyl-lysines and displace the SEC-PTEFb complex from 
active chromatin, thus inhibiting the transcription of MLL fusions target genes and 
suppressing its oncogenic programs. 
